Canopy Growth (CGC) Q1 2026: Cannabis Revenue Jumps 24% as Cost Cuts Hit 85% of Target
Canopy Growth’s Q1 saw a sharp rebound in cannabis revenue, driven by Canadian adult-use and medical channels, while aggressive cost discipline delivered $17 million in annualized savings, already 85% of the full-year target. Despite margin pressure from product mix and international headwinds, management is doubling down on operational fundamentals and expects margin improvement in the back half. Investors should watch for execution in Europe and the upcoming Storz & Bickel device launch to influence the next phase of growth and profitability.
Summary
- Canadian Adult-Use Cannabis Surges: Distribution expansion and targeted portfolio drove standout growth in a competitive market.
- Cost Structure Reset Accelerates: SG&A cuts and operational streamlining are reshaping the business for leaner execution.
- Margin Recovery in Focus: Management is prioritizing gross margin gains and automation to stabilize profitability ahead.
Performance Analysis
Canopy Growth’s Q1 2026 results underscored a decisive pivot toward disciplined execution, with cannabis net revenue up 24% year over year, led by a 43% jump in Canadian adult-use and 13% growth in medical cannabis. The company credited tighter product focus, expanded distribution, and improved retail execution for these gains, with nearly 4,800 new points of sale added in the quarter. International performance was mixed: Germany delivered triple-digit growth, but Poland struggled with regulatory and supply issues, and Australia faced price compression.
The Storz & Bickel, premium vaporizer segment, saw revenue drop 25% as it cycled a tough comp and faced weaker U.S. demand. Gross margin contraction in both segments weighed on adjusted EBITDA, with labor and third-party costs for high-demand products and lower-margin sales in Poland cited as key drivers. Still, free cash flow improved materially, with outflows shrinking to $12 million from $56 million last year, and SG&A was cut by 21% through structural headcount and overhead reductions.
- Distribution Expansion: Canadian adult-use saw nearly 4,800 new retail points, fueling order volume and shelf presence.
- Cost Reduction Progress: $17 million of $20 million targeted annualized savings achieved, with 15% SG&A headcount cut.
- Margin Pressure Persists: Cannabis gross margin fell to 24%, but sequential improvement signals early benefit from efficiency moves.
Overall, Canopy is showing early signs of a turnaround in core cannabis, though margin recovery and international execution remain critical levers for sustainable profitability.
Executive Commentary
"I'm very encouraged by the performance that our cannabis business delivered in the first quarter. Cannabis net revenue grew 24% year over year, while our team managed its way through significant structural changes while making meaningful progress on our cost reduction initiatives."
Luc Mongeau, Chief Executive Officer
"SG&A expenses in the first quarter declined 21% as compared to last year, primarily due to ongoing cost reduction initiatives. These savings reflect permanent structural changes across multiple functions and markets aimed at aligning our cost base with the size and priorities of our business."
Tom Stewart, Interim Chief Financial Officer
Strategic Positioning
1. Canadian Cannabis: Focused Portfolio, Retail Reach
Canopy’s adult-use strategy is now centered on high-velocity SKUs and targeted innovation, with the Claiborne infused pre-rolls and Tweed branded vapes leading demand. The company’s refined sales model and expanded national reach are driving both shelf presence and larger order sizes, positioning Canopy to outpace many peers in a crowded market.
2. International Markets: Germany Growth, Poland Setback
International cannabis sales returned to growth, powered by Germany’s triple-digit gains, but Poland’s performance suffered from regulatory and supply allocation issues. Leadership is prioritizing infrastructure and process improvements in Europe, with a new managing director tasked to build a scalable commercial strategy and restore growth in Poland.
3. Storz & Bickel: Navigating Demand Cycles, New Launch Ahead
The vaporizer business, Storz & Bickel, faced a tough quarter but is poised for a product refresh, with a new device launch set for the coming weeks. Management expects this innovation, paired with in-sourcing manufacturing, to reignite sales and support margin recovery in H2.
4. Margin Discipline: Automation and Pricing
Gross margin improvement is now a company-wide mandate, with automation, selective price increases, and supply prioritization underway. The goal is to exit the year with cannabis margins in the low to mid-30s, up from the current 24% level, supported by operational leverage and improved product mix.
5. U.S. Optionality: Selective Investment, Awaiting Regulatory Shifts
While federal rescheduling remains uncertain, Canopy USA’s focus is on driving profitability in select geographies and supporting operating companies like Acreage and Jetty through cost control and targeted growth, positioning for upside if U.S. reform accelerates.
Key Considerations
Q1 marked a pivot from restructuring to operational execution, with management signaling a clear focus on margin recovery, international expansion, and disciplined capital allocation. The path to profitability now hinges on execution in both core and emerging markets, as well as successful commercialization of new products.
Key Considerations:
- Canadian Market Share Battle: Sustained distribution gains and targeted SKUs are key to defending and growing share amid price compression and regulatory complexity.
- European Execution Risk: Near-term growth depends on resolving Poland’s supply issues and scaling in Germany, with infrastructure and local leadership now in place.
- Storz & Bickel Turnaround: Success of the upcoming device launch and manufacturing efficiency will determine whether this segment returns to growth in H2.
- Cash Flow and Debt Management: Material improvement in free cash flow, reduced interest expense, and $50 million term loan prepayment planned by year-end add financial flexibility.
- Margin Expansion Initiatives: Automation, price actions, and mix shift toward higher-margin products are critical to achieving the stated margin targets.
Risks
Margin recovery remains vulnerable to product mix, labor costs, and international volatility, particularly in Europe where regulatory and supply disruptions persist. Storz & Bickel’s demand in the U.S. is soft, and the pace of U.S. regulatory change is uncertain, limiting near-term upside from Canopy USA. Execution on automation and pricing is required to hit margin goals, and any delays could prolong adjusted EBITDA losses.
Forward Outlook
For Q2 and the balance of fiscal 2026, Canopy Growth guided to:
- Continued top-line growth in Canadian medical and adult-use cannabis, driven by expanded distribution and new product launches.
- International acceleration in Europe, with new product registrations and increased supply expected to drive growth in Germany and Poland in H2.
For full-year 2026, management expects:
- Significant improvement in free cash flow as lower interest costs and working capital discipline take hold.
- Gross margin improvement to low to mid-30s in cannabis, supported by automation and pricing actions.
Management highlighted:
- Margin expansion and operational discipline as top priorities for the remainder of the year.
- Storz & Bickel’s new device launch as a potential catalyst for segment recovery.
Takeaways
Canopy’s Q1 signals a credible return to growth in core cannabis, but the company’s ability to translate cost cuts and operational gains into sustainable margin expansion remains the central question for investors.
- Execution on Margin Recovery: The planned automation and supply prioritization must deliver margin gains to support long-term profitability, especially as product mix shifts toward labor-intensive SKUs.
- International Leverage: Resolving supply and regulatory bottlenecks in Europe, especially in Poland and Germany, will be crucial to unlocking the next leg of growth.
- Near-term Watchpoints: Investors should monitor the impact of the Storz & Bickel device launch, pace of European recovery, and sequential margin trends as key markers of execution quality in coming quarters.
Conclusion
Canopy Growth is delivering on revenue growth and cost discipline, but must now prove it can restore margins and drive cash flow as it scales in Canada and Europe. Execution on automation, pricing, and international expansion will determine whether this turnaround gains traction or stalls amid ongoing industry volatility.
Industry Read-Through
Canopy’s results highlight a broader shift in the cannabis sector toward operational discipline and targeted portfolio management, as price compression and regulatory hurdles persist across markets. The Canadian market remains fiercely competitive, rewarding those with supply chain agility and retail execution. Internationally, Germany’s growth underscores the potential for rapid expansion as reforms take hold, but Poland’s challenges are a cautionary tale on regulatory risk. Vaporizer demand softness in the U.S. also signals ongoing consumer headwinds for premium devices, suggesting peers may face similar pressure. Margin recovery and cash flow discipline are emerging as the new benchmarks for sector leadership.